Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Califano · SciRah

Researcher profile · Semantic Scholar

R. Califano

Share profile

R. Califano — researcher profile on SciRah

h-index: 38
Works: 233
Citations: 7,990

Most-cited papers

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen V. Liu, M. Reck, A. Mansfield, T. Mok +16 more
2021Journal of Clinical Oncology738 citations Open access
Semantic Scholar
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
B. Cho, Shun Lu, E. Felip, A. Spira +53 more
2024New England Journal of Medicine403 citations Open access
Semantic Scholar
Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.
D. Camidge, H. R. Kim, M. Ahn, J. Yang +18 more
2021Journal of Thoracic Oncology292 citations Open access
Semantic Scholar
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
M. Boyer, M. Şendur, D. Rodríguez-Abreu, Keunchil Park +16 more
2021Journal of Clinical Oncology204 citations Open access
Semantic Scholar
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
D. Fennell, S. Ewings, C. Ottensmeier, R. Califano +35 more
2021The Lancet Oncology192 citations Open access
Semantic Scholar
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
J. Yang, Shun Lu, H. Hayashi, E. Felip +52 more
2025New England Journal of Medicine129 citations
Semantic Scholar
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
S. Lee, C. Schulz, K. Prabhash, D. Kowalski +22 more
2023The Lancet124 citations
Semantic Scholar
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
E. Lim, D. Waller, K. Lau, J. Steele +49 more
2024The Lancet Respiratory Medicine102 citations Open access
Semantic Scholar
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
L. Paz-Ares, Hossein Borghaei, Stephen V. Liu, S. Peters +25 more
2025The Lancet93 citations
Semantic Scholar
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
M. Reck, R. Dziadziuszko, Shunichi Sugawara, S. Kao +20 more
2024Lung Cancer87 citations
Semantic Scholar
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
W. Liang, K. Cai, Chun Chen, Hai-Quan Chen +41 more
2020Translational Lung Cancer Research80 citations Open access
Semantic Scholar
Using DNA sequencing data to quantify T cell fraction and therapy response
R. Bentham, K. Litchfield, T. Watkins, Emilia L. Lim +288 more
2021Nature62 citations Open access
Semantic Scholar
RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
S. Novello, R. Califano, Niels Reinmuth, A. Tamma +1 more
2023The Oncologist42 citations Open access
Semantic Scholar
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
M. Ahn, H. R. Kim, Jie Yang, Ji-Yun Han +17 more
2022Clinical Lung Cancer36 citations Open access
Semantic Scholar
Recent advances and future strategies in first-line treatment of ES-SCLC.
I. Gomez-Randulfe, R. Leporati, Brinda Gupta, Stephen V. Liu +1 more
2024European Journal of Cancer33 citations Open access
Semantic Scholar
PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial
D. Fennell, C. Ottensmeier, R. Califano, G. Hanna +18 more
202129 citations Open access
Semantic Scholar
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).
B. Besse, L. Paz-Ares, Solange Peters, F. Cappuzzo +8 more
2023Journal of Clinical Oncology24 citations
Semantic Scholar
A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future
Si-Jia Ren, An-Yi Xu, Yi-Li Lin, D. Camidge +7 more
2021Translational Lung Cancer Research19 citations Open access
Semantic Scholar
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
B. Qiu, K. Cai, Chun Chen, Jun Chen +74 more
2021Translational Lung Cancer Research17 citations Open access
Semantic Scholar
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions
C. Ackermann, H. Adderley, A. Ortega-Franco, Adeel M. Khan +2 more
2020Drugs17 citations
Semantic Scholar
Evolving treatment for advanced Non-small cell lung cancer harbouring common EGFR activating mutations.
I. Gomez-Randulfe, F. Monaca, D. Planchard, E. Bria +1 more
2025Critical reviews in oncology/hematology16 citations
Semantic Scholar
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
A. Ortega-Franco, V. Calvo, Fabio Franco, M. Provencio +1 more
2020Translational Lung Cancer Research16 citations Open access
Semantic Scholar
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
Laura Moliner, N. Zellweger, S. Schmid, M. Bertschinger +31 more
2024JTO Clinical and Research Reports15 citations Open access
Semantic Scholar
Experience With the Routine Use of Electronic Patient-Reported Outcome Measures for Patients With Lung Cancer
C. Crockett, J. Price, Mai Pham, D. Abdulwahid +23 more
2023JCO Clinical Cancer Informatics15 citations
Semantic Scholar
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer
A. Rimner, W. Lai, R. Califano, S. Jabbour +9 more
2022Clinical Lung Cancer15 citations
Semantic Scholar
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.
E. Felip, B. C. Cho, Vanesa Gutiérrez, A. Alip +16 more
2024Journal of Clinical Oncology14 citations
Semantic Scholar
Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis.
F. Monaca, I. Gomez-Randulfe, G. Walls, Ornella Cantale +17 more
2025European Journal of Cancer11 citations Open access
Semantic Scholar
Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis
I. Gomez-Randulfe, Sofía Silva Díaz, C. Escriu, S. Mohammed +16 more
2024Therapeutic Advances in Medical Oncology11 citations Open access
Semantic Scholar
Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index
A. Ortega-Franco, C. Hodgson, H. Raja, M. Carter +7 more
2022Targeted oncology11 citations
Semantic Scholar
Antibody-Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond.
F. Monaca, I. Gomez-Randulfe, J. Torres Jiménez, Muskan Agarwal +3 more
2026Journal of Thoracic Oncology10 citations
Semantic Scholar
First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis.
I. Gomez-Randulfe, Lauren A. Scanlon, Mathew Carter, Laura Moliner +7 more
2025Lung Cancer10 citations
Semantic Scholar
Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis
G. Tsakonas, S. Ekman, A. Koulouris, H. Adderley +2 more
2023International Journal of Cancer10 citations Open access
Semantic Scholar
Association between immunotherapy timing and efficacy in non-small cell lung cancer: a comprehensive analysis at a high-volume specialist centre
I. Gomez-Randulfe, Mark Pearce, Daniel Netto, Rebecca Ward +1 more
2025Translational Lung Cancer Research9 citations Open access
Semantic Scholar
Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.
F. Monaca, I. Gomez-Randulfe, A. Parreira, Vito Longo +15 more
2025European Journal of Cancer9 citations Open access
Semantic Scholar
Amivantamab plus chemotherapy vs chemotherapy in EGFR -mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.
R. Califano, A. Passaro, J. Tan, A. Blasco +13 more
2025Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
D. Fennell, K. Hill, Min Zhang, C. Poile +36 more
2025Nature Communications7 citations Open access
Semantic Scholar
A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer
T. Jordan, T. Nuamek, I. Fornacon-Wood, R. Califano +6 more
2024Frontiers in Oncology7 citations Open access
Semantic Scholar
Novel therapeutic strategies for recurrent SCLC.
L. Moliner, Bingnan Zhang, G. Lamberti, A. Ardizzoni +2 more
2023Critical reviews in oncology/hematology7 citations
Semantic Scholar
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
J. Sands, M. Reck, A. Navarro, A. Chiang +10 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
A. Rimner, W. Lai, R. Califano, S. Jabbour +8 more
20216 citations
Semantic Scholar
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
S. Oresti, Fabio Salomone, Antonio Nuccio, F. Ogliari +21 more
2025EClinicalMedicine5 citations Open access
Semantic Scholar
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
S. Peters, C. Schulz, Martin Reck, K. Prabhash +23 more
2025Journal of Thoracic Oncology4 citations
Semantic Scholar
Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
K. Hockenhull, A. Ortega-Franco, R. Califano
2021Translational Lung Cancer Research4 citations Open access
Semantic Scholar
A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).
A. Dowlati, R. Califano, Koichi Goto, M. Pérol +15 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.
P. Tomasini, Ó. Juan-Vidal, R. Califano, Chien-Chung Lin +28 more
2025Clinical Lung Cancer3 citations
Semantic Scholar
Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy.
Stephen V. Liu, C. Guibert, Elvire Pons Tostivint, R. Califano +13 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Service Evaluation of MyChristie-MyHealth, an Electronic Patient-Reported Outcome Measure Integrated Into Clinical Cancer Care
Lee A Shipman, James Price, D. Abdulwahid, N. Bayman +18 more
2024JCO Clinical Cancer Informatics3 citations
Semantic Scholar
Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L.
D. Camidge, H. R. Kim, M. Ahn, Jie Yang +16 more
2022Journal of Clinical Oncology3 citations
Semantic Scholar
9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
J. Menis, P. Bironzo, G. Radj, L. Greillier +16 more
20203 citations Open access
Semantic Scholar
Overall survival according to timing of immune checkpoint inhibitors administration in patients with advanced cancer: results from a large single-centre cohort analysis
T. Bosetti, O. Kennedy, R. Califano, T. Waddell +4 more
2026British Journal of Cancer2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

I. Gomez-Randulfe×8
Invite
I. Gomez-Randulfe — researcher profile on SciRah
E. Felip×7
Invite
E. Felip — researcher profile on SciRah
Paul Taylor×7
Invite
Paul Taylor — researcher profile on SciRah
Y. Summers×7
Invite
Y. Summers — researcher profile on SciRah

×6

Invite

M. Reck — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah

C. Faivre-Finn×6

Invite

C. Faivre-Finn — researcher profile on SciRah

Invite

D. Camidge — researcher profile on SciRah

Invite

F. Cappuzzo — researcher profile on SciRah

L. Cove-Smith×5

Invite

L. Cove-Smith — researcher profile on SciRah

Invite

F. Monaca — researcher profile on SciRah

Invite

K. Prabhash — researcher profile on SciRah